Executive Board

Both Executive Board members, Dr. Bernd Wegener and Dr. Andreas Bergmann, possess decade-long experience in biotechnology and the pharmaceutical industry. Both were founding members of  B.R.A.H.M.S. GmbH, a successfull biotech company, specialized in the development of blood biomarkers. In 2009, the company was sold for approx. 330 million Euros to Thermo Fisher Scientific. Dr. Bernd Wegener is member of Executive Board of the Federal Association of the Pharmaceutical Industry (Bundesverband der pharmazeutischen Industrie).

Dr. Bernd Wegener

Dr. Bernd Wegener

Chief Executive Officer | CEO

  • Born 1947, Veterinarian
  • 1974 – 1993 Executive Management functions at Boehringer Ingelheim, Degussa Pharma-Gruppe, Marion Merrell Dow
  • 1994 Initiator of the Management Buy-Out of B.R.A.H.M.S. GmbH
  • Chief Executive Officer of B.R.A.H.M.S. AG until 2009
  • Executive Board member of the Federal Association of the Pharmaceutical Industry between 2000 – 2014
  • Entrepreneurship with several companies since 2010
  • Honorary membership in various Company Advisory Boards and Foundation Excecutive Boards

Dr. Bernd Wegener
Dr. Andreas Bergmann
Dr. Andreas Bergmann

Dr. Andreas Bergmann

Chief Scientific Officer | CSO

  • Born 1961, Biochemist
  • Founder and co-founder, i.e. B.R.A.H.M.S. GmbH, in.vent Diagnostica GmbH, InVivo BioTech Services GmbH, Bioassays GmbH, sphingotec GmbH, sphingotec Therapeutics GmbH, Oncoprevent GmbH, My Life Diagnostics GmbH, AngioBiomed GmbH, AdrenoMed AG, immunochemical intelligence – ICI GmbH, NeuroTen GmbH, DBI AG
  • Inventor of over 100 patent families in the field of medical diagnostics and therapy
  • Well above 100 publications in peer-reviewed journals
  • Chairman of the „Waltraut Bergmann Stiftung zur Förderung der Krebsforschung“

Senior Management

Dr. Frauke Hein


Chief Business Officer | CBO

Dr. Joachim Struck 


Head of Research & Development

Dr. Jens Zimmermann

Medical Doktor

Chief Medical Officer | CMO